Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.52 |
| ▸ | MERTK | Q12866 | 4/20 | 0.48 |
| ▸ | DNM2 | P50570 | 2/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.40 |
| ▸ | GAS6 | Q14393 | 3/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15181300 | 0.90 | SYK (0.44) | HRH4MERTKDNM2PKMSYK | |
| SCHEMBL11988212 | 0.86 | DNM2 (0.48) | HRH4MERTKDNM2TLR8MAPK8 | |
| SCHEMBL11988630 | 0.83 | EIF2AK2 (0.48) | HRH4PKMSYKPLK1 | |
| SCHEMBL11988195 | 0.83 | CCR4 (0.52) | HRH4DNM2SYK | |
| SCHEMBL11988196 | 0.80 | CCR4 (0.49) | DNM2PKMSYKPLK1CA1 | |
| SCHEMBL24650717 | 0.79 | MKNK1 (0.48) | PKMSYKPLK1 | |
| SCHEMBL12963477 | 0.79 | PKM (0.57) | HRH4TLR8PKMSYKPLK1 | |
| SCHEMBL13403107 | 0.78 | HRH4 (0.56) | HRH4MERTKDNM2TLR8MAPK8 | |
| SCHEMBL16844971 | 0.78 | HRH4 (0.52) | HRH4SYK | |
| SCHEMBL19477219 | 0.78 | DNM2 (0.71) | HRH4MERTKDNM2TLR8MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247562-B2 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2012-08-21 | — | — | US | disclosed |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC4 | HRH4 58/4885MERTK 4563/4885DNM2 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.